8-K: SeaStar Medical Announces $6 Million Registered Direct Offering

SeaStar Medical has entered into a securities purchase agreement for a $6 million registered direct offering with a single institutional investor.

Summary

• SeaStar Medical has announced a securities purchase agreement for a registered direct offering with an institutional investor.
• The offering involves the issuance and sale of 3,529,412 shares of common stock (or pre-funded warrants) and warrants to purchase 3,529,412 shares of common stock.
• The combined offering price is $1.70 per share (or $1.699 for pre-funded warrants).
• Pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately.
• Warrants have an exercise price of $1.70 per share, exercisable upon shareholder approval, and expire five years after approval.
• The offering is expected to close around February 3, 2025, pending customary conditions.
• Gross proceeds are expected to be approximately $6 million.
• SeaStar Medical plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the capital raise provides financial resources, it also introduces potential dilution for existing shareholders. The company's future prospects depend on the effective use of these funds.

Positives

• The offering provides SeaStar Medical with $6 million in gross proceeds.
• The funds will be used for general corporate purposes, providing financial flexibility.
• The pre-funded warrants offer immediate access to equity at a nominal exercise price.
• The offering is structured as a registered direct offering, providing liquidity for the investor.

Negatives

• The offering involves the issuance of a significant number of new shares, which may dilute existing shareholders.
• The warrants, if exercised, could further dilute existing shareholders.
• The offering was made without an underwriter or a placement agent and we are not paying underwriting discounts or commissions. We are required to pay to H.C. Wainwright & Co. a cash fee equal to 7.0% of the aggregate gross proceeds in this offering and to issue Wainwright warrants to purchase 247,059 shares of Common Stock at an exercise price of $2.125 per share (the Placement Agent Warrants)

Risks

• The closing is subject to customary conditions and may not occur as expected.
• The intended use of proceeds is for general corporate purposes, which may not directly translate to increased shareholder value.
• The company may not be able to obtain regulatory approval of its SCD product candidates.
• The company may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• The company and its current and future collaborators may be unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• The company may never achieve or sustain profitability.
• The company may not be able to access funding under existing agreements.
• Third-parties suppliers and manufacturers may not be able to fully and timely meet their obligations.
• There is a risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medicals products and services.
• The company may be unable to secure or protect its intellectual property.

Future Outlook

SeaStar Medical intends to use the net proceeds of this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

Industry Context

This announcement reflects a common financing strategy for small-cap biotech companies to raise capital for ongoing operations and development programs.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as Athersys and Cytosorbents, have also utilized registered direct offerings to raise capital.
• The terms of this offering, including the combined price of $1.70 per share and accompanying warrants, are within the typical range for such transactions in the current market environment.
• The use of proceeds for working capital and capital expenditures is consistent with industry norms for companies in the development and commercialization stages.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's financial stability may improve due to the infusion of capital.
• Employees may benefit from increased job security and potential for growth.
• Customers may benefit from the company's ability to invest in product development and commercialization.

Next Steps

• The offering is expected to close on or about February 3, 2025, subject to customary closing conditions.
• SeaStar Medical intends to use the net proceeds for general corporate purposes.
• The Company has agreed to hold a special meeting of stockholders within 120 days of the closing of the offering to approve the exercise of the Common Warrants and issuance of the shares of Common Stock underlying the Common Warrants (the Stockholder Approval Date).

Key Dates